TriMark Publications estimates that the global market for professionally performed point of care testing was $14.46 billion in 2016. This segment is expected to reach $18.57 billion in 2021, with a compound annual growth (CAGR) of 7% over the next five years. This report provides:

• An overview of the global market for professionally administered point of care testing. This report is the only point of care testing survey that examines ONLY the professionally administered sector of the market, confined to hospitals, clinics, and doctor’s office testing. For clarity, it does not include patient self-testing or home testing.
• Analyses of global market size, with data from 2014 to 2016 and projections through 2021.
• The U.S. and important international markets are analyzed. The U.S. is recognized as the largest single country market for professional POCT products; Asia (which includes Japan, China and India for the purposes of this report) represents a major market, but there are significant differences in growth rates for each of the individual countries.
• Estimates of growth, trends, key issues and drivers in point of care IVD testing through 2021.
• An overview of professionally administered point of care testing (as opposed to home care testing), with particular emphasis on market size and growth rate for glucose monitoring, blood gas & electrolytes, coagulation, cardiac markers, substance abuse, infectious disease, urine strip tests, pregnancy tests, occult blood, cholesterol and HIV for each major country market is discussed.
• A complete discussion of point of care instruments used in the major sectors of this area.
• A discussion of business activity in this professionally administered sector with possible new company entrants to the market.
• A discussion of related issues, such as growth regulators, government regulation, reimbursement trends and revenue threats, as well as sector consolidation, acquisition & licensing.
• New Innovative technology platforms and data management and connectivity.
  Comprehensive company profiles of major players in the field of point of care testing.

TriMark Publications This TriMark Publications report describes nine main medical imaging sectors: X-ray, ultrasound, computed tomography (CT), positron emission tomography (PET), single photon emission tomography (SPECT), magnetic resonance imaging (MRI), nuclear medicine (NM), mammography and fluoroscopy. This report covers:

• Globally, X-ray is the most frequently used imaging procedure with about 108 million X-ray exams per year. MRI is second with 26 million examinations per year. PET, SPECT, CT and nuclear medicine rank third with 30 million examinations per year.
• Picture archiving and communication systems (PACS) and contrast agents are the sub-segments in medical imaging market that have gained significant growth in recent years.
• The global medical imaging industry is primed to experience significant growth through the next decade.
• This report surveys almost all of the companies known to be marketing, manufacturing or developing medical imaging equipment and supplies in the world.
• An overview of the global market for medical imaging.
  Analyses of global market size, with data from 2015, with estimates for 2016, and projections through 2021.
• Estimates of growth, trends, key issues and drivers in medical imaging through 2021.
• A discussion of business activity in this sector with possible new company entrants to the market.
• Discussion of related issues, such as growth regulators, government regulation, reimbursement trends and revenue threats, as well as sector consolidation, acquisition & licensing.
• Innovative technology platforms and data management and connectivity.
• Comprehensive company profiles of major players in the field.

TriMark Publications estimates that the global market for molecular diagnostics for infectious disease testing is $4.1 billion in 2016. This segment is expected to reach $5.9 billion in 2020, with a compound annual growth (CAGR) of 21% over the next five years. This report provides:

• An overview of the global market for molecular diagnostics for infectious disease testing. Analyses of global market size, with data from 2012, 2013, 2014 and 2015, with estimates for 2016, and projections through 2020. The U.S. and international markets are analyzed.
• Estimates of growth and trends in advanced MD infectious disease testing through 2020.
• An overview of infectious disease testing, with particular emphasis on hepatitis, HIV, human papilloma virus, influenza, STD Testing (including Chlamydia/Gonorrhea Molecular Diagnostic Testing), tuberculosis, Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci.
• A discussion of business activity in this sector with possible new company entrants to the market.
• A discussion of related issues, such as government regulation, reimbursement trends and revenue threats.
• Comprehensive company profiles of major players in the field of molecular diagnostics for infectious disease testing.

TriMark Publications estimates that the global market for in vitro diagnostic tests for cardiac biomarkers was worth $7.2 billion in 2016. This segment is expected to reach $13.1 billion in 2021, growing at a compound annual growth (CAGR) of 11.5% over the next five years. This report provides:

• An overview of the global market for in vitro diagnostic (IVD) tests for cardiac biomarkers.
• Analyses of global market size, with data from 2011 to 2016, estimates for 2017, and projections through 2021.
• The U.S. and important international markets are analyzed. The U.S. is recognized as the largest single country market for cardiac biomarker IVD and point of care (POC) products.
• Estimates of growth, trends, key issues and drivers in cardiac biomarker testing through 2021.
• An overview of point of care testing with particular emphasis on market size and growth rate for individual cardiac markers for major markets.
• An overview of testing for biomarkers of cardiovascular disease, including sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis.
• A discussion of business activity in this sector, including strategies for growth in emerging markets.
• A discussion of related issues, such as growth regulators, government regulation, reimbursement trends, as well as sector consolidation, acquisition & licensing.
• Comprehensive company profiles of major players in the field of cardiac biomarker testing.